Sponsor & Developer Portfolio

Novartis Pharmaceuticals

Clinical development pipeline, platform architecture, and registered trial tracking for Novartis Pharmaceuticals vaccine candidates.

2
Candidates
2
Target Diseases
2
Linked Studies

Development Phase Distribution

Discontinued / Inactive: 1 Phase 2 Clinical Trial: 1

Platform Technologies

mRNA: 1 Biological (unspecified platform): 1

Target Pathogens & Indications

COVID-19 Immunoglobulin A Nephropathy (IgAN)

Vaccine Pipeline Candidates (2)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals

mRNA COVID-19 vaccine

Target: COVID-19

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2023-04-14 (registry estimate)
Phase 2 Clinical Trial ctgov-zigakibart-novartis-pharmaceuticals

zigakibart

Target: Immunoglobulin A Nephropathy (IgAN)

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2030-07-12 (registry estimate)

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →